Actively Recruiting
A Double-Blind Placebo-Controlled Study Evaluating Oral ACP-211 Monotherapy for Adults with Major Depressive Disorder Not Adequately Treated by Antidepressants
Led by ACADIA Pharmaceuticals Inc. · Updated on 2026-10-05
153
Participants Needed
28
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ACP-211, a medication, to treat adults with major depressive disorder MDD who have not improved with current antidepressant therapy, including those with treatment-resistant depression. This phase 2 trial aims to determine if ACP-211 reduces depression symptoms better than a placebo and to monitor any side effects experienced by participants. Participants are randomly assigned to receive either 600 mg or 300 mg of ACP-211, or a matching placebo, all taken orally twice a week. The study is double-blind, meaning neither participants nor researchers know who receives which treatment, to fairly assess the effects. The main treatment period lasts 28 days with doses given twice weekly. During the study, participants are assessed for changes in depression severity using the Montgomery-sberg Depression Rating Scale MADRS at baseline, day 2, and day 28, among other measures. Additional evaluations include clinical global impression scores and remission rates. Safety and side effects are closely monitored throughout. The total participation time spans from screening to the end of treatment and follow-up, concluding around 28 days after treatment begins.
CONDITIONS
Brief Title
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Research Team
S
Sandy Filosi
L
Lori Lykens
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here